EHP-102

EHP-102, known in the scientific literature as VCE-003.2, is an aminoquinone derived from cannabigerol (CBG), obtained by chemical modification of the hemp molecule. Described in 2016 by the team of Díaz-Alonso, it has only negligible affinity for the CB1 and CB2 receptors (predicted Ki above 40 µM) and acts through PPARγ, a nuclear receptor involved in controlling inflammation, with an IC50 of 1.2 µM in a competitive binding assay. In mice, models of Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and synucleinopathy have been used to assess neuroprotective effects. The data are exclusively preclinical: no clinical trial is published in the sources consulted.

Source

Semi-synthetic derivative of cannabigerol (CBG), the non-psychotropic hemp phytocannabinoid, itself chemically modified to obtain the molecule. No natural occurrence is reported in the sources consulted.

No biosynthetic pathway: EHP-102 is not produced by any living organism. It derives from chemical synthesis, by oxidation of the cannabigerol ring to a quinone, then introduction of a nitrogen function. Only the class of transformation is described here.

European Union

No harmonised control measure at European Union level is documented in the sources consulted for EHP-102, and the compound appears in no schedule of the 1971 Convention (INCB, Green List 2026). Any control therefore falls under national law. No marketing authorisation or novel food authorisation is documented.

France

Not classified to date. EHP-102 is not named in any annex of the order of 22 February 1990 or in the ANSM consolidated list (update of 16 February 2026). Its structure meets none of the generic definitions of that list: it has no indole, indazole, pyrrole, indene, cyclohexylphenol or thiazole core. It is not a tetrahydrocannabinol, and the benzo[c]chromene core clause of the decision of 22 May 2024 does not apply, as the molecule has no such ring. The absence of classification is not an authorisation: no marketing authorisation, as a medicine or as a novel food, is documented in the sources consulted.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

1. 1Díaz-Alonso et coll., VCE-003.2, nouveau dérivé du cannabigérol, favorise la survie des progéniteurs neuronaux et atténue la symptomatologie dans des modèles murins de maladie de Huntington, Scientific Reports 2016 (new tab)PMID 27430371
2. 2García et coll., VCE-003.2, dérivé quinone du cannabigérol, dans un modèle de Parkinson induit par inflammation : sites de liaison possibles sur PPARγ, J Neuroinflammation 2018 (new tab)PMID 29338785
3. 3Burgaz et coll., administration orale du VCE-003.2 contre la neurodégénérescence liée à l'inflammation dans la maladie de Parkinson expérimentale, Molecules 2019 (new tab)PMID 31349553
4. 4Burgaz et coll., VCE-003.2 comme agent modificateur de la maladie dans un modèle murin de synucléinopathie, Behav Brain Funct 2024 (new tab)PMID 39487447
5. 5Granja et coll., une quinone du cannabigérol atténue la neuro-inflammation dans un modèle chronique de sclérose en plaques, J Neuroimmune Pharmacol 2012 (new tab)PMID 22971837
6. 6Rodríguez-Cueto et coll., effets neuroprotecteurs du VCE-003.2 chez des souris SOD1(G93A), modèle de sclérose latérale amyotrophique, Biochem Pharmacol 2018 (new tab)PMID 30076846
7. 7ANSM, liste consolidée des substances classées comme stupéfiants (mise à jour du 16 février 2026) (new tab)
8. 8ANSM, décision du 22 mai 2024 portant modification de la liste des substances classées comme stupéfiants (clause du noyau benzo[c]chromène) (new tab)
9. 9INCB, Green List 2026 (conventions de 1961 et 1971) (new tab)
10. 10PubChem CID 91864651 : EHP-102 (identifiants) (new tab)
11. 11EHP-102, désignation et composé associé (repère tertiaire : Wikipédia) (new tab)

SMILES

CCCCCC1=C(C(=C(C(=O)C1=O)C/C=C(\C)/CCC=C(C)C)O)NCC

InChIKey

MRCQPMQBCKEOCU-SAPNQHFASA-N

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.